PharmaBlock Sciences (Nanjing), Inc.

SZSE:300725 Stock Report

Market Cap: CN¥6.9b

PharmaBlock Sciences (Nanjing) Valuation

Is 300725 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300725 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300725 (CN¥35.48) is trading above our estimate of fair value (CN¥3.39)

Significantly Below Fair Value: 300725 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300725?

Other financial metrics that can be useful for relative valuation.

300725 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA20.7x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does 300725's PE Ratio compare to its peers?

The above table shows the PE ratio for 300725 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.7x
600789 Shandong Lukang PharmaceuticalLtd
16.9xn/aCN¥6.9b
603229 Zhejiang Ausun Pharmaceutical
24.7xn/aCN¥6.7b
600976 Jianmin Pharmaceutical GroupLtd
13.7x20.7%CN¥6.9b
600557 Jiangsu Kanion PharmaceuticalLtd
15.3x21.5%CN¥8.0b
300725 PharmaBlock Sciences (Nanjing)
38.7x25.7%CN¥6.9b

Price-To-Earnings vs Peers: 300725 is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the peer average (17.7x).


Price to Earnings Ratio vs Industry

How does 300725's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 300725 is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the CN Pharmaceuticals industry average (29x).


Price to Earnings Ratio vs Fair Ratio

What is 300725's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300725 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.7x
Fair PE Ratio31.9x

Price-To-Earnings vs Fair Ratio: 300725 is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the estimated Fair Price-To-Earnings Ratio (31.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300725 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥35.48
CN¥36.50
+2.9%
9.6%CN¥40.00CN¥33.00n/a2
Oct ’25CN¥37.80
CN¥36.50
-3.4%
9.6%CN¥40.00CN¥33.00n/a2
Sep ’25CN¥26.98
CN¥37.50
+39.0%
6.7%CN¥40.00CN¥35.00n/a2
Aug ’25CN¥30.21
CN¥37.50
+24.1%
6.7%CN¥40.00CN¥35.00n/a2
Jul ’25CN¥27.11
CN¥37.50
+38.3%
6.7%CN¥40.00CN¥35.00n/a2
Mar ’25CN¥31.09
CN¥58.00
+86.6%
10.3%CN¥64.00CN¥52.00n/a2
Feb ’25CN¥28.14
CN¥58.00
+106.1%
10.3%CN¥64.00CN¥52.00n/a2
Jan ’25CN¥39.27
CN¥58.00
+47.7%
10.3%CN¥64.00CN¥52.00n/a2
Dec ’24CN¥43.85
CN¥58.00
+32.3%
10.3%CN¥64.00CN¥52.00n/a2
Nov ’24CN¥44.61
CN¥58.00
+30.0%
10.3%CN¥64.00CN¥52.00n/a2
Aug ’24CN¥50.96
CN¥88.00
+72.7%
4.5%CN¥92.00CN¥84.00CN¥30.212
Jul ’24CN¥48.43
CN¥88.00
+81.7%
4.5%CN¥92.00CN¥84.00CN¥27.112
Jun ’24CN¥52.93
CN¥88.00
+66.3%
4.5%CN¥92.00CN¥84.00CN¥31.332

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies